Company intelligence / Profile preview

Angion Biomedica Corp.

Uniondale, New York, United Statesangion.com ↗

Ownership: Private
Development stage: Other

Overview

Angion Biomedica experienced setbacks in clinical trials. Their ANG-3777 failed in Phase 2 and Phase 3 trials. In 2022, they discontinued the JUNIPER Phase 2 study of ANG-3070 for kidney disease due to safety concerns after a patient experienced an unexpected decline in kidney function. As of June 1, 2023, Angion Biomedica was acquired by Elicio Therapeutics in a reverse merger.

Therapeutic areas: PulmonologyImmunologyNephrology
Modalities: Small moleculesTyrosine kinase inhibitors
Industry: Biotech

Partnerships

Academic institutions for clinical trialsPharmaceutical companies for drug development

Beyond the preview

Go deeper on Angion Biomedica Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angion Biomedica Corp..